235 related articles for article (PubMed ID: 37433717)
1. Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures.
Wei F; Azuma K; Nakahara Y; Saito H; Matsuo N; Tagami T; Kouro T; Igarashi Y; Tokito T; Kato T; Kondo T; Murakami S; Usui R; Himuro H; Horaguchi S; Tsuji K; Murotani K; Ban T; Tamura T; Miyagi Y; Sasada T
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37433717
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
[TBL] [Abstract][Full Text] [Related]
6. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
7. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
Mazzaschi G; Minari R; Zecca A; Cavazzoni A; Ferri V; Mori C; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Missale G; Petronini PG; Quaini F; Tiseo M
Lung Cancer; 2020 Oct; 148():1-11. PubMed ID: 32768804
[TBL] [Abstract][Full Text] [Related]
8. Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer.
Rich P; Mitchell RB; Schaefer E; Walker PR; Dubay JW; Boyd J; Oubre D; Page R; Khalil M; Sinha S; Boniol S; Halawani H; Santos ES; Brenner W; Orsini JM; Pauli E; Goldberg J; Veatch A; Haut M; Ghabach B; Bidyasar S; Quejada M; Khan W; Huang K; Traylor L; Akerley W
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706885
[TBL] [Abstract][Full Text] [Related]
9. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
11. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
12. Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer.
Jiang T; Liu H; Qiao M; Li X; Zhao C; Su C; Ren S; Zhou C
Clin Lung Cancer; 2018 Mar; 19(2):e177-e184. PubMed ID: 29175386
[TBL] [Abstract][Full Text] [Related]
13. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
14. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
Boeri M; Milione M; Proto C; Signorelli D; Lo Russo G; Galeone C; Verri C; Mensah M; Centonze G; Martinetti A; Sottotetti E; Pastorino U; Garassino MC; Sozzi G
Clin Cancer Res; 2019 Apr; 25(7):2166-2173. PubMed ID: 30617131
[TBL] [Abstract][Full Text] [Related]
15. Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Kim H; Lim DH; Kwon YS; Kim MA; Park KU
Anticancer Res; 2023 May; 43(5):2343-2349. PubMed ID: 37097676
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.
Yoshida H; Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Ajimizu H; Yamazoe M; Kuninaga K; Ogimoto T; Hosoya K; Itotani R; Sakamori Y; Kim YH; Hirai T
Eur J Cancer; 2021 Feb; 144():317-325. PubMed ID: 33385948
[TBL] [Abstract][Full Text] [Related]
17. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
18. Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Zhang L; Zhang T; Shang B; Li Y; Cao Z; Wang H
Scand J Immunol; 2021 Sep; 94(3):e13087. PubMed ID: 35226388
[TBL] [Abstract][Full Text] [Related]
19. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
20. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
